Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Generate Biomedicines, Inc.NASDAQ: GENB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization of $3.27M in Q1 FY2026
Q1 FY2026 depreciation & amortization was $3.27M.
Context
- Depreciation & amortization amounted to 41.3% of revenue in FY2025, down 33.7 pp from a year earlier.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 13.18M USD
- Year-over-year change
- -14.1%
- 1-year CAGR
- -14.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.18M | -14.1% |
| FY2024 | 2024-12-31 | 15.35M | — |
Depreciation & Amortization vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 depreciation & amortization of $13.18M is the 2nd largest of the 5 companies compared; the peer median is $9.05M.
- Its year-over-year change of -14.1% is the lowest of 5, against a peer median of -9.3%.
- Depreciation & amortization amounts to 41.3% of revenue for GENB, versus a peer median of 113.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $13.18M | -14.1% | — | 41.3% |
| LTM Mar 2026 | $11.4M | -12.6% | -3.6% | 620.8% | |
| LTM Mar 2026 | $6.7M | -8.9% | +8.8% | 6.7% | |
| LTM Mar 2026 | $2.35M | -9.8% | +26.6% | 180.4% | |
| Peer median (excluding GENB) | $9.05M | -9.3% | +2.6% | 113.9% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.